share_log

Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price Target

Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price Target

傑富瑞將BioCryst Pharma升級爲收購,宣佈目標股價爲11美元
Benzinga ·  2023/08/04 08:41

Jefferies analyst Maury Raycroft upgrades BioCryst Pharma (NASDAQ:BCRX) from Hold to Buy and announces $11 price target.

傑富瑞分析師莫里·雷克羅夫特將BioCryst Pharma(納斯達克股票代碼:BCRX)從持有上調至買入,並宣佈了11美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論